Generic Name and Formulations:
Levalbuterol (as HCl) (single-isomer albuterol) 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL; per vial; inhalation soln; preservative-free.
Indications for XOPENEX:
Initially 0.63mg by nebulization 3 times daily at 6–8 hr intervals; may increase to 1.25mg 3 times daily.
<6 years: not recommended. 6–11 years: 0.31mg by nebulization 3 times daily; max 0.63mg 3 times daily.
Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and consider adding an antiinflammatory (eg, corticosteroids). Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Seizure disorders. Diabetes. Hyperthyroidism. Renal impairment; monitor (esp. in elderly). Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Caution with other drugs that may lower serum potassium (eg, diuretics). Monitor digoxin.
Accidental injury, bronchitis, dizziness, pain, pharyngitis, rhinitis, vomiting; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects, hypokalemia.
Vials (YES); HFA (NO)
Inhaler w. actuator (80inh)—8.4g, (200 inh)—15g; Soln 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL—24 vials; Concentrate 1.25mg/0.5mL—30 vials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML